Answers are grounded in this paper and cite their sources.
Combretastatin A’s (CA1–CA5) are important cis-stilbenoid-type anticancer natural products that suffer from short biological half-life and cis-trans isomerization in vivo. Herein, the synthesis of a novel class of benzylidene diarylheptanoids based on combretastatin A and mono-keto curcumin is demonstrated. Where the cis-form of combretastatin A is locked to mono-keto curcumin. Aldol condensation of combretastatin aldehyde with a ketone (acetone/cyclopentanone/cyclohexanone/N-methyl-4-piperidone) in the presence of a base (LiOH/Ba(OH)₂) affords target compounds in 36–70% yield. Target compounds and their precursors, combretastatin aldehydes, were completely characterized by spectroscopic methods and single-crystal XRD studies. Our efforts offer natural products (combretastatin A and mono-keto curcumin), based novel and isomerically stable benzylidene diarylheptanoids of great potential for cancer chemotherapy.
No takes yet. Share an insight, caveat, or question.
Ponraj et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: